Zafiris Kartasis

Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

Meletios Α. Dimopoulos, Ramón García‐Sánz, Maria Gavriatopoulou et al. · Blood · 2013 · 207 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

Efstathios Kastritis, Konstantinos Zervas, Argiris Symeonidis et al. · Leukemia · 2009 · 187 citations

Medicine, Hematology, Oncology +17

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents

Meletios Α. Dimopoulos, Sosana Delimpasi, Eirini Katodritou et al. · Annals of Oncology · 2013 · 157 citations

Medicine, Hematology, Nephrology +8

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

Evangelos Terpos, Eirini Katodritou, Anastasia Pouli et al. · European Journal Of Haematology · 2010 · 145 citations

Medicine, Oncology, Chemotherapy +11

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

Maria Gavriatopoulou, Ramón García‐Sánz, Efstathios Kastritis et al. · Blood · 2016 · 80 citations · Full text

Medicine, Neurology, Rheumatology +1